Search

Your search keyword '"Balmaña, Judith"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Balmaña, Judith" Remove constraint Author: "Balmaña, Judith" Database Springer Nature Journals Remove constraint Database: Springer Nature Journals
47 results on '"Balmaña, Judith"'

Search Results

1. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

2. Genetic and clinical characterization of a novel FH founder mutation in families with hereditary leiomyomatosis and renal cell cancer syndrome

3. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

6. An spanish study of secondary findings in families affected with mendelian disorders: choices, prevalence and family history

8. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

9. Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

10. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

11. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

12. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study

15. Clinical consequences of BRCA2 hypomorphism

16. Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants

17. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk

18. Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study

19. Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

21. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings

23. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

24. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

25. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

27. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

34. Characterization of four novel BRCA2 large genomic rearrangements in Spanish breast/ovarian cancer families: review of the literature, and reevaluation of the genetic mechanisms involved in their origin

35. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members

36. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer

37. Evidence for a link between TNFRSF11A and risk of breast cancer

38. International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation

43. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers

Catalog

Books, media, physical & digital resources